PHILADELPHIA, March 6,
2024 /PRNewswire/ -- Geneos Therapeutics, a
clinical stage biotherapeutics company focused on the development
of personalized therapeutic cancer vaccines (PTCV), today announced
the upcoming presentation of two posters sharing new clinical data
from its Phase 1b/2a GT-30 study of
GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with
advanced hepatocellular carcinoma, at the 2024 American Association
for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting
will be held in San Diego from
April 5-10.
Details of the poster presentations are as follows:
Title: Personalized neoantigen DNA vaccine GNOS-PV02
and pembrolizumab as second-line treatment for advanced
hepatocellular carcinoma
Presenting Author: Mark Yarchoan, MD
Abstract Number: 1191
Poster Board Number: 25
Session Title: Tumor Immune Response 1
Session Date and Time: Sunday, Apr 7,
2024, 1:30 pm - 5:00 pm PT
Location: San Diego
Convention Center, Poster Section 47
Title: Detection of circulating tumor DNA predicts
survival in advanced HCC patients treated with personalized
therapeutic DNA cancer vaccine in combination with immune
checkpoint blockade
Presenting Author: Jian Yan,
PhD
Abstract Number: 976
Poster Board Number: 17
Session Title: Circulating Nucleic Acids 1
Session Date and Time: Sunday, April
7, 2024, 1:30 pm - 5:00 pm
PT
Location: San Diego
Convention Center, Poster Section 40
About Geneos Therapeutics
Geneos Therapeutics, a clinical stage biotherapeutics company, is
developing personalized therapeutic cancer vaccines (PTCVs) that
may serve an important role in new immunotherapeutic paradigms for
cancer. The company's approach, using its proprietary GT-EPIC™
platform, is to target neoantigens (abnormal mutations produced by
cancer cells) from individual patient tumors to develop novel and
uniquely personalized treatments for cancer. Planning is underway
for a potentially registrational clinical trial in advanced
hepatocellular carcinoma. For more information, please
visit www.geneostx.com.
View original
content:https://www.prnewswire.com/news-releases/geneos-therapeutics-to-present-new-clinical-data-on-gnos-pv02-at-the-2024-american-association-for-cancer-research-aacr-annual-meeting-302080667.html
SOURCE Geneos Therapeutics, Inc.